Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof,

##STR00001##

wherein X is O, S or NR.sup.5; or X is C(R.sup.6)C(R.sup.7), wherein the carbon atom bonded to R.sup.6 is also bonded to the carbon atom bonded to R.sup.4, and the carbon atom bonded to R.sup.7 is also bonded to the phenyl ring moiety in Formula 1; and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, G and W are as defined in the disclosure.
Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound or a composition of the invention.

The present invention relates to novel benzofuran-2-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

The present invention relates to novel benzofuran-2-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

The present invention describes indenocarbazole derivatives having electron- and hole-transporting properties, in particular for use in the emission and/or charge-transport layer of electroluminescent devices or as matrix material. The invention furthermore relates to a process for the preparation of the compounds according to the invention and to electronic devices comprising same. ##STR00001##

The present invention describes indenocarbazole derivatives having electron- and hole-transporting properties, in particular for use in the emission and/or charge-transport layer of electroluminescent devices or as matrix material. The invention furthermore relates to a process for the preparation of the compounds according to the invention and to electronic devices comprising same. ##STR00001##

Disclosed herein are heterocyclic compounds that activate GLP-1R pathways. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the GLP-1R agonists are disclosed, alone or in combination with other therapeutic agents, for the treatment of diabetes, obesity, and other diseases or conditions dependent on GLP-1R pathways.

An organic electroluminescence device includes a first electrode and a second electrode facing each other, and a plurality of organic layers between the first electrode and the second electrode, wherein at least one of the organic layers includes an amine compound represented by Formula 1 below. The organic electroluminescence device may have improved luminous efficiency. ##STR00001##